Amyloid PET ligands for dementia

PET Clinics

Volumn 5, Issue 1, 2010, Pages 33-53

  Villemagne, Victor L ^a,b   Rowe, Christopher C ^a  

^a AUSTIN HEALTH   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

A ; Alzheimer's disease; Brain imaging; Positron emission tomography

Indexed keywords

2 (1 (6 [(2 FLUOROETHYL)(METHYL)AMINO] 2 NAPHTHYL)ETHYLIDENE)MALONITRILE F 18; AMYLOID; AV 45; AZD 2138; AZD 2138 C 11; AZD 4694; AZD 4694 F 18; BAY 94 9172; BF 227; BF 227 C 11; BIOLOGICAL MARKER; FLORBETABEN; FLORPIRAMINE; GE 067; GE 067 F 18; PITTSBURGH COMPOUND B; SB 13; SB 13 C 11; ST 1859; ST 1859 C 11; TRACER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN REGION; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HUMAN; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 77956642230     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.12.008     Document Type: Review

References (244)

1. C.L. Masters, R. Cappai, and K.J. Barnham Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics J Neurochem 97 6 2006 1700 1725 (Pubitemid 43873662)
2. J. Schneider, J. Murray, and S. Banerjee EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: I - factors associated with carer burden Int J Geriatr Psychiatry 14 8 1999 651 661 (Pubitemid 29403284)
3. D.A. Bennett Part I. Epidemiology and public health impact of Alzheimer's disease Dis Mon 46 10 2000 657 665
4. N. Johnson, T. Davis, and N. Bosanquet The epidemic of Alzheimer's disease. How can we manage the costs? Pharmacoeconomics 18 3 2000 215 223
5. D.J. Selkoe Alzheimer's disease is a synaptic failure Science 298 5594 2002 789 791
6. C.L. Masters Neuropathology of Alzheimer's disease A. Burns, J. O'Brien, D. Ames, Dementia 3rd edition 2005 Hodder Arnold London 393 407
7. C.L. Masters, and K. Beyreuther The neuropathology of Alzheimer's disease in the year 2005 M.F. Beal, A.E. Lang, A.C. Ludolph, Neurodegenerative diseases: neurobiology, pathogenesis and therapeutics 2005 Cambridge University Press Cambridge 433 440
8. K. Jellinger Morphology of Alzheimer disease and related disorders K. Maurer, P. Riederer, H. Beckmann, Alzheimer disease: epidemiology, neuropathology, neurochemistry, and clinics 1990 Springer-Verlag Berlin 61 77
9. K.A. Jellinger, and C. Bancher Neuropathology of Alzheimer's disease: a critical update J Neural Transm suppl 54 1998 77 95
10. M.L. Michaelis, R.T. Dobrowsky, and G. Li Tau neurofibrillary pathology and microtubule stability J Mol Neurosci 19 3 2002 289 293
11. C.L. Masters, G. Simms, and N.A. Weinman Amyloid plaque core protein in Alzheimer disease and down syndrome Proc Natl Acad Sci U S A 82 12 1985 4245 4249
12. R. Cappai, and A.R. White Amyloid beta Int J Biochem Cell Biol 31 9 1999 885 889
13. V.L. Villemagne, R. Cappai, and K.J. Barnham The Abeta centric pathway of Alzheimer's disease C.J. Barrow, B.J. Small, Abeta peptide and Alzheimer's disease 2006 Springer-Verlag London 5 32
14. S.M. Greenberg, G.W. Rebeck, and J.P. Vonsattel Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy Ann Neurol 38 2 1995 254 259
15. M.S. Mega, I.D. Dinov, and V. Porter Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose F 18 positron emission tomographic study Arch Neurol 62 5 2005 721 728
16. C.A. McLean, R.A. Cherny, and F.W. Fraser Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease Ann Neurol 46 6 1999 860 866
17. P.V. Arriagada, J.H. Growdon, and E.T. Hedley-Whyte Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease Neurology 42 3 Pt 1 1992 631 639
18. L.F. Lue, Y.M. Kuo, and A.E. Roher Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease Am J Pathol 155 3 1999 853 862
19. J. Wang, D.W. Dickson, and J.Q. Trojanowski The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging Exp Neurol 158 2 1999 328 337
20. J. Naslund, V. Haroutunian, and R. Mohs Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline JAMA 283 12 2000 1571 1577
21. C.A. McLean, K. Beyreuther, and C.L. Masters Amyloid Abeta levels in Alzheimer's disease - a diagnostic tool and the key to understanding the natural history of Abeta? J Alzheimers Dis 3 3 2001 305 312
22. D.M. Walsh, I. Klyubin, and J.V. Fadeeva Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo Nature 416 6880 2002 535 539
23. D.M. Walsh, I. Klyubin, and G.M. Shankar The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention Biochem Soc Trans 33 Pt 5 2005 1087 1090
24. G. McKhann, D. Drachman, and M. Folstein Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease Neurology 34 1984 939 944
25. R.C. Petersen Mild cognitive impairment: current research and clinical implications Semin Neurol 27 1 2007 22 31
26. R.C. Petersen Mild cognitive impairment: transition between aging and Alzheimer's disease Neurologia 15 3 2000 93 101
27. R.C. Petersen, J.C. Stevens, and M. Ganguli Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the quality standards subcommittee of the American academy of neurology Neurology 56 9 2001 1133 1142
28. R.C. Petersen Aging, mild cognitive impairment, and Alzheimer's disease Neurol Clin 18 4 2000 789 806
29. R.C. Petersen, G.E. Smith, and S.C. Waring Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 3 1999 303 308
30. C.L. Masters, and K. Beyreuther Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway Brain 129 Pt 11 2006 2823 2839
31. V.L. Villemagne, S. Ng, and R. Cappai La Lunga Attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease Neuroradiol J 19 2006 51 75
32. I.G. McKeith, D.W. Dickson, and J. Lowe Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology 65 12 2005 1863 1872
33. R.A. Armstrong, N.J. Cairns, and P.L. Lantos Beta-amyloid deposition in the temporal lobe of patients with dementia with Lewy bodies: comparison with non-demented cases and Alzheimer's disease Dement Geriatr Cogn Disord 11 4 2000 187 192
34. O. Pletnikova, N. West, and M.K. Lee Abeta deposition is associated with enhanced cortical a-synuclein lesions in Lewy body diseases Neurobiol Aging 26 2005 1183 1192
35. R.T. Mott, D.W. Dickson, and J.Q. Trojanowski Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias J Neuropathol Exp Neurol 64 5 2005 420 428
36. N. Sergeant, A. Delacourte, and L. Buee Tau protein as a differential biomarker of tauopathies Biochim Biophys Acta 1739 2-3 2005 179 197
37. G. Halliday, T. Ng, and M. Rodriguez Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria Acta Neuropathol (Berl) 104 1 2002 72 78
38. N.J. Cairns, E.H. Bigio, and I.R. Mackenzie Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration Acta Neuropathol 114 1 2007 5 22
39. M. Neumann, L.K. Kwong, and D.M. Sampathu TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis Arch Neurol 64 10 2007 1388 1394
40. M.J. de Leon, A. Convit, and S. DeSanti Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease Int Psychogeriatr 9 Suppl 1 1997 183 190 [discussion: 247-52]
41. B.C. Dickerson, I. Goncharova, and M.P. Sullivan MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease Neurobiol Aging 22 5 2001 747 754
42. R.J. Killiany, T. Gomez-Isla, and M. Moss Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease Ann Neurol 47 4 2000 430 439
43. Y. Xu, C.R. Jack Jr., and P.C. O'Brien Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD Neurology 54 9 2000 1760 1767
44. C.A. Mathis, B.J. Lopresti, and W.E. Klunk Impact of amyloid imaging on drug development in Alzheimer's disease Nucl Med Biol 34 7 2007 809 822
45. V.L. Villemagne, M.T. Fodero-Tavoletti, and K.E. Pike The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias Mol Neurobiol 38 1 2008 1 15
46. N. Okamura, T. Suemoto, and S. Furumoto Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease J Neurosci 25 47 2005 10857 10862
47. A. Ojida, T. Sakamoto, and M.A. Inoue Fluorescent BODIPY-based Zn(II) complex as a molecular probe for selective detection of neurofibrillary tangles in the brains of Alzheimer's disease patients J Am Chem Soc 131 18 2009 6543 6548
48. M. Maruyama, J. Maeda, and B. Ji In-vivo optical and PET detections of fibrillar tau lesions in a mouse model of tauopathies [abstract] Alzheimers Dement 55 4 Suppl 1 2009 P209 P210
49. H.I. Sair, P.M. Doraiswamy, and J.R. Petrella In vivo amyloid imaging in Alzheimer's disease Neuroradiology 46 2 2004 93 104
50. V.L. Villemagne, C.C. Rowe, and S. Macfarlane Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease J Clin Neurosci 12 3 2005 221 230
51. C.A. Mathis, W.E. Klunk, and J.C. Price Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies Arch Neurol 62 2 2005 196 200
52. D.R. Thal, U. Rub, and C. Schultz Sequence of Abeta-protein deposition in the human medial temporal lobe J Neuropathol Exp Neurol 59 8 2000 733 748
53. C.D. Link, C.J. Johnson, and V. Fonte Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34 Neurobiol Aging 22 2 2001 217 226
54. W.E. Klunk, M.L. Debnath, and J.W. Pettegrew Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease Neurobiol Aging 15 6 1994 691 698
55. B.J. Bacskai, W.E. Klunk, and C.A. Mathis Imaging amyloid-beta deposits in vivo J Cereb Blood Flow Metab 22 9 2002 1035 1041
56. W.E. Klunk, B.J. Bacskai, and C.A. Mathis Imaging Aβ plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative J Neuropathol Exp Neurol 61 9 2002 797 805
57. B.J. Bacskai, G.A. Hickey, and J. Skoch Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice Proc Natl Acad Sci U S A 100 21 2003 12462 12467
58. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents J Med Chem 46 13 2003 2740 2754
59. Y. Wang, W.E. Klunk, and G.F. Huang Synthesis and evaluation of 2-(3′-iodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease J Mol Neurosci 19 1-2 2002 11 16
60. Y. Wang, C.A. Mathis, and G.F. Huang Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives J Mol Neurosci 20 3 2003 255 260
61. L. Helmuth Long-awaited technique spots Alzheimer's toxin Science 297 2002 752 753
62. 11C-labelled thioflavin-T analogues for imaging amyloid plaques in Alzheimer's disease J. Labelled Cpd Radiopharm 44 Suppl 1 2001 S26 S28
63. W.E. Klunk, Y. Wang, and G.F. Huang Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain Life Sci 69 13 2001 1471 1484
64. W.E. Klunk, Y. Wang, and G.F. Huang The binding of 2-(4′- methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component J Neurosci 23 6 2003 2086 2092
65. C.A. Mathis, B.J. Bacskai, and S.T. Kajdasz A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain Bioorg Med Chem Lett 12 3 2002 295 298
66. Z.P. Zhuang, M.P. Kung, and C. Hou Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates J Med Chem 44 12 2001 1905 1914
67. H.F. Kung, C.W. Lee, and Z.P. Zhuang Novel stilbenes as probes for amyloid plaques J Am Chem Soc 123 50 2001 12740 12741
68. D.M. Skovronsky, B. Zhang, and M.P. Kung In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease Proc Natl Acad Sci U S A 97 13 2000 7609 7614
69. M.P. Kung, C. Hou, and Z.P. Zhuang Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in Alzheimer's disease J Mol Neurosci 19 1-2 2002 7 10
70. Z.P. Zhuang, M.P. Kung, and C. Hou IBOX(2-(4′-dimethylaminophenyl)- 6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain Nucl Med Biol 28 8 2001 887 894
71. C.W. Lee, Z.P. Zhuang, and M.P. Kung Isomerization of (Z, Z) to (E, E)1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in strong base: probes for amyloid plaques in the brain J Med Chem 44 14 2001 2270 2275
72. M.L. Schmidt, T. Schuck, and S. Sheridan The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy) styrylbenzene (BSB), labels diverse β-pleated sheet structures in postmortem human neurodegenerative disease brains Am J Pathol 159 3 2001 937 943
73. Z.P. Zhuang, M.P. Kung, and A. Wilson Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain J Med Chem 46 2 2003 237 243
74. M.P. Kung, C. Hou, and Z.P. Zhuang IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques Brain Res Bull 956 2 2002 202 210
75. M. Ono, M.P. Kung, and C. Hou Benzofuran derivatives as Abeta-aggregate-specific imaging agents for Alzheimer's disease Nucl Med Biol 29 6 2002 633 642
76. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease Nucl Med Biol 30 6 2003 565 571
77. M.P. Kung, D.M. Skovronsky, and C. Hou Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients J Mol Neurosci 20 1 2003 15 24
78. M.P. Kung, Z.P. Zhuang, and C. Hou Characterization of radioiodinated ligand binding to amyloid beta plaques J Mol Neurosci 20 3 2003 249 254
79. C.W. Lee, M.P. Kung, and C. Hou Dimethylamino-fluorenes: ligands for detecting beta-amyloid plaques in the brain Nucl Med Biol 30 6 2003 573 580
80. R.E. Majocha, J.M. Reno, and R.P. Friedland Development of a monoclonal antibody specific for b/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy J Nucl Med 33 12 1992 2184 2189
81. L.C. Walker, D.L. Price, and M.L. Voytko Labelling of cerebral amyloid in vivo with a monoclonal antibody J Neuropathol Exp Neurol 53 4 1994 377 383
82. V.M. Lee Related Amyloid binding ligands as Alzheimer's disease therapies Neurobiol Aging 23 6 2002 1039 1042
83. J.R. Marshall, E.R. Stimson, and J.R. Ghilardi Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo Bioconjug Chem 13 2 2002 276 284
84. A. Kurihara, and W.M. Pardridge Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections Bioconjug Chem 11 3 2000 380 386
85. J.F. Poduslo, M. Ramakrishnan, and S.S. Holasek In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques J Neurochem 102 2 2007 420 433
86. J. Shi, G. Perry, and M.S. Berridge Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice J Nucl Med 43 8 2002 1044 1051
87. K. Shoghi-Jadid, G.W. Small, and E.D. Agdeppa Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease Am J Geriatr Psychiatry 10 1 2002 24 35
88. W.E. Klunk, H. Engler, and A. Nordberg Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 3 2004 306 319
89. 11C]SB-13 PET Am J Geriatr Psychiatry 12 6 2004 584 595
90. M. Bauer, O. Langer, and P. Dal-Bianco A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease Clin Pharmacol Ther 80 3 2006 216 227
91. Y. Kudo, N. Okamura, and S. Furumoto 2-(2-[2-Dimethylaminothiazol-5-yl] ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients J Nucl Med 48 4 2007 553 561
92. S. Nyberg, M.E. Jonhagen, and Z. Cselenyi Detection of amyloid in Alzheimer's disease with positron emission tomography using [(11)C]AZD2184 Eur J Nucl Med Mol Imaging 36 2009 1859 1863
93. C.C. Rowe, U. Ackerman, and W. Browne Imaging of amyloid beta in Alzheimer's disease with (18)F-BAY94-9172, a novel PET tracer: proof of mechanism Lancet Neurol 7 2 2008 129 135
94. K. Serdons, C. Terwinghe, and P. Vermaelen Synthesis and evaluation of (18)F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease J Med Chem 52 2009 7090 7102
95. D.F. Wong, P. Rosenberg, and Y. Zhou In vivo imaging of amyloid deposition in Alzheimer's disease using the novel radioligand [F-18]AV-45 [abstract] J Nucl Med 49 2008 214P
96. C. Opazo, S. Luza, and V.L. Villemagne Radioiodinated clioquinol as a biomarker for beta-amyloid:Zn complexes in Alzheimer's disease Aging Cell 5 1 2006 69 79
97. 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease J Nucl Med 47 5 2006 748 754
98. I. Maezawa, H.S. Hong, and R. Liu Congo red and thioflavin-T analogs detect Abeta oligomers J Neurochem 104 2 2008 457 468
99. T. Tomiyama, T. Nagata, and H. Shimada A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia Ann Neurol 63 3 2008 377 387
100. P.J. Song, S. Bernard, and P. Sarradin IMPY, a potential beta-amyloid imaging probe for detection of prion deposits in scrapie-infected mice Nucl Med Biol 35 2 2008 197 201
101. K.S. Lin, M.L. Debnath, and C.A. Mathis Synthesis and beta-amyloid binding properties of rhenium 2-phenylbenzothiazoles Bioorg Med Chem Lett 19 8 2009 2258 2262
102. W. Qu, M.P. Kung, and C. Hou Novel styrylpyridines as probes for SPECT imaging of amyloid plaques J Med Chem 50 9 2007 2157 2165
103. W. Qu, M.P. Kung, and C. Hou Radioiodinated aza-diphenylacetylenes as potential SPECT imaging agents for beta-amyloid plaque detection Bioorg Med Chem Lett 17 13 2007 3581 3584
104. K. Serdons, T. Verduyckt, and J. Cleynhens Synthesis and evaluation of a (99m)Tc-BAT-phenylbenzothiazole conjugate as a potential in vivo tracer for visualization of amyloid beta Bioorg Med Chem Lett 17 22 2007 6086 6090
105. J.C. Price, W.E. Klunk, and B.J. Lopresti Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B J Cereb Blood Flow Metab 25 11 2005 1528 1547
106. A. Lockhart, L. Ye, and D.B. Judd Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils J Biol Chem 280 9 2005 7677 7684
107. L. Ye, J.L. Morgenstern, and A.D. Gee Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils J Biol Chem 280 25 2005 23599 23604
108. W.E. Klunk, B.J. Lopresti, and M.D. Ikonomovic Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain J Neurosci 25 46 2005 10598 10606
109. J. Maeda, B. Ji, and T. Irie Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography J Neurosci 27 41 2007 10957 10968
110. M.T. Fodero-Tavoletti, C.C. Rowe, and C.A. McLean Characterization of PiB binding to white matter in Alzheimer disease and other dementias J Nucl Med 50 2 2009 198 204
111. H. LeVine 3rd Quantification of beta-sheet amyloid fibril structures with thioflavin T Meth Enzymol 309 1999 274 284
112. A. Lockhart, J.R. Lamb, and T. Osredkar PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis Brain 130 Pt 10 2007 2607 2615
113. M.T. Fodero-Tavoletti, D.P. Smith, and C.A. McLean In vitro characterization of Pittsburgh compound-B binding to Lewy bodies J Neurosci 27 39 2007 10365 10371
114. L. Ye, A. Velasco, and G. Fraser In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain J Neurochem 105 4 2008 1428 1437
115. M.D. Ikonomovic, W.E. Klunk, and E.E. Abrahamson Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain 131 Pt 6 2008 1630 1645
116. J.Q. Trojanowski Emerging Alzheimer's disease therapies: focusing on the future Neurobiol Aging 23 6 2002 985 990
117. M.P. Kung, C. Hou, and Z.P. Zhuang Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease Brain Res 1025 1-2 2004 98 105
118. N. Okamura, T. Suemoto, and H. Shimadzu Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain J Neurosci 24 10 2004 2535 2541 (Pubitemid 38327966)
119. Y. Kudo Development of amyloid imaging PET probes for an early diagnosis of Alzheimer's disease Minim Invasive Ther Allied Technol 15 4 2006 209 213
120. M.T. Fodero-Tavoletti, R.S. Mulligan, and N. Okamura In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies Eur J Pharmacol 617 2009 54 58
121. N. Okamura, S. Furumoto, and K. Furukawa PET imaging of brain Amyloid deposits using BF-227 and its derivative [abstract] Alzheimers Dement 4 Suppl 1 2008 T383
122. A.E. Johnson, F. Jeppsson, and J. Sandell AZD2184: a radioligand for sensitive detection of beta-amyloid deposits J Neurochem 108 5 2009 1177 1186
123. E.D. Agdeppa, V. Kepe, and K. Shoghi-Jadid In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer's disease patient: a case study J Nucl Med 42 Suppl 1 2001 65P
124. E.D. Agdeppa, V. Kepe, and J. Liu Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease J Neurosci 21 24 2001 RC189
125. J.R. Barrio, S.C. Huang, and G. Cole PET imaging of tangles and plaques in Alzheimer disease with a highly hydrophobic probe J Labelled Compd Radiopharm 42 1999 S194 S195
126. M. Bresjanac, L.M. Smid, and T.D. Vovko Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro J Neurosci 23 22 2003 8029 8033
127. G.W. Small, E.D. Agdeppa, and V. Kepe In vivo brain imaging of tangle burden in humans J Mol Neurosci 19 3 2002 323 327
128. G.W. Small, V. Kepe, and L.M. Ercoli PET of brain amyloid and tau in mild cognitive impairment N Engl J Med 355 25 2006 2652 2663
129. 18F]FDDNP Synapse 62 6 2008 472 475
130. 18F-FDDNP PET J Nucl Med 50 2 2009 191 197
131. W.J. Shih, W.R. Markesbery, and D.B. Clark Iodine-123 HIPDM brain imaging findings in subacute spongiform encephalopathy (Creutzfeldt-Jakob disease) J Nucl Med 28 9 1987 1484 1487
132. P.W. Thompson, L. Ye, and J.L. Morgenstern Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies J Neurochem 109 2 2009 623 630
133. W. Zhang, S. Oya, and M.P. Kung F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain J Med Chem 48 19 2005 5980 5988 (Pubitemid 41324608)
134. W. Zhang, S. Oya, and M.P. Kung F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain Nucl Med Biol 32 8 2005 799 809 (Pubitemid 41505313)
135. P.M. Doraiswamy, M. Farmer, and R. Holub Relationship between regional amyloid levels and cognitive performance in healthy controls, MCI subjects, and patients with Alzheimer's: Phase II results from a florpiramine F18 PET imaging study Alzheimers Dement 5 4 Suppl 1 2009 P77
136. R. Sperling, K. Johnson, and M.J. Pontecorvo PET imaging of beta-amyloid with florpiramine F18 (18F-AV-45): Preliminary results from a phase II study of cognitively normal elderly subjects, individuals with mild cognitive impairment, and patients with a clinical diagnosis of Alzheimer's disease [abstract] Alzheimers Dement 5 4 Suppl 1 2009 P197
137. 18F-labelled 2-(4′-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB Bioorg Med Chem Lett 19 3 2009 602 605
138. C.A. Mathis, M.D. Ikonomovic, and N.S. Mason Pharmacologic and pharmacokinetic equivalence studies of GE-067 to PiB [abstract] Alzheimers Dement 5 4 Suppl 1 2009 P262
139. K. Van Laere, R. Vanderberghe, and A. Ivaniou Correlation between 18F-GE-067 and 11C-PIB uptake in Alzheimer's disease and MCI [abstract] Alzheimers Dement 5 4 Suppl 1 2009 P263
140. A.K. Sundgren-Andersson, S.P.S. Svensson, and B.M. Swahn AZD4694: fluorinated positron emission tomography (PET) radioligand for detection of beta-amyloid deposits [abstract] Alzheimers Dement 5 4 Suppl 1 2009 P267 P268
141. C.C. Rowe, S. Ng, and U. Ackermann Imaging beta-amyloid burden in aging and dementia Neurology 68 20 2007 1718 1725
142. A. Forsberg, H. Engler, and O. Almkvist PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiol Aging 29 10 2008 1456 1465
143. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease Neurology 67 3 2006 446 452
144. S.N. Gomperts, D.M. Rentz, and E. Moran Imaging amyloid deposition in Lewy body diseases Neurology 71 12 2008 903 910
145. W. Maetzler, I. Liepelt, and M. Reimold Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics Neurobiol Dis 34 1 2009 107 112
146. B.J. Lopresti, W.E. Klunk, and C.A. Mathis Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis J Nucl Med 46 12 2005 1959 1972
147. C.L. Joachim, J.H. Morris, and D.J. Selkoe Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease Am J Pathol 135 2 1989 309 319
148. W.E. Klunk, J.C. Price, and C.A. Mathis Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees J Neurosci 27 23 2007 6174 6184
149. 11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease Brain 131 Pt 7 2008 1845 1853
150. A.L. Boxer, G.D. Rabinovici, and V. Kepe Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease Neurology 69 3 2007 283 290
151. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease J Neurol Neurosurg Psychiatr 66 2009 1537 1544
152. A. Johansson, I. Savitcheva, and A. Forsberg [(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results Parkinsonism Relat Disord 14 4 2008 345 347
153. 11C]PIB positron emission tomography J Neurol Neurosurg Psychiatr 79 12 2008 1331 1338
154. 11C]PIB binding in Parkinson's disease dementia Neuroimage 39 3 2008 1027 1033
155. S.Y. Ng, V.L. Villemagne, and C.L. Masters Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B Arch Neurol 64 8 2007 1140 1144
156. H. Braak, and E. Braak Frequency of stages of Alzheimer-related lesions in different age categories Neurobiol Aging 18 4 1997 351 357
157. D.R. Thal, U. Rub, and M. Orantes Phases of A beta-deposition in the human brain and its relevance for the development of AD Neurology 58 2002 1791 1800
158. B.J. Bacskai, M.P. Frosch, and S.H. Freeman Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report Arch Neurol 64 3 2007 431 434
159. S.E. Arnold, L.Y. Han, and C.M. Clark Quantitative neurohistological features of frontotemporal degeneration Neurobiol Aging 21 6 2000 913 919
160. V. Leinonen, I. Alafuzoff, and S. Aalto Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B Arch Neurol 65 10 2008 1304 1309
161. K.A. Johnson, M. Gregas, and J.A. Becker Imaging of amyloid burden and distribution in cerebral amyloid angiopathy Ann Neurol 62 3 2007 229 234
162. A. Drzezga, T. Grimmer, and G. Henriksen Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease Neuroimage 39 2 2008 619 633
163. H. Engler, A.F. Santillo, and S.X. Wang In vivo amyloid imaging with PET in frontotemporal dementia Eur J Nucl Med Mol Imaging 35 1 2008 100 106
164. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration Neurology 68 15 2007 1205 1212
165. G.D. Rabinovici, W.J. Jagust, and A.J. Furst Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia Ann Neurol 64 4 2008 388 401
166. J.C. Morris, M. Storandt, and J.P. Miller Mild cognitive impairment represents early-stage Alzheimer disease Arch Neurol 58 3 2001 397 405 (Pubitemid 32217456)
167. 11C]PIB uptake is increased in mild cognitive impairment Neurology 68 19 2007 1603 1606
168. K.E. Pike, G. Savage, and V.L. Villemagne Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease Brain 130 Pt 11 2007 2837 2844
169. V.L. Villemagne, K.E. Pike, and D. Darby Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease Neuropsychologia 46 6 2008 1688 1697
170. H.J. Aizenstein, R.D. Nebes, and J.A. Saxton Frequent amyloid deposition without significant cognitive impairment among the elderly Arch Neurol 65 11 2008 1509 1517
171. L. Davies, B. Wolska, and C. Hilbich A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques Neurology 38 11 1988 1688 1693
172. M.S. Forman, E.J. Mufson, and S. Leurgans Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis Neurology 68 10 2007 757 763
173. J.C. Morris, and A.L. Price Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease J Mol Neurosci 17 2 2001 101 118
174. P.R. Hof, P. Glannakopoulos, and C. Bouras The neuropathological changes associated with normal brain aging Histol Histopathol 11 4 1996 1075 1088
175. D.R. Thal, K. Del Tredici, and H. Braak Neurodegeneration in normal brain aging and disease Sci Aging Knowledge Environ 2004 23 2004 pe26
176. L. Backman, S. Jones, and A.K. Berger Cognitive impairment in preclinical
177. B.J. Small, E. Gagnon, and B. Robinson Early identification of cognitive deficits: preclinical Alzheimer's disease and mild cognitive impairment Geriatrics 62 4 2007 19 23
178. J.L. Price, and J.C. Morris Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann Neurol 45 3 1999 358 368
179. A. Nordberg Amyloid imaging in Alzheimer's disease Curr Opin Neurol 20 4 2007 398 402
180. A.M. Fagan, C.M. Roe, and C. Xiong Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 64 3 2007 343 349
181. A.M. Fagan, M.A. Mintun, and R.H. Mach Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans Ann Neurol 59 3 2006 512 519
182. J. Koivunen, T. Pirttila, and N. Kemppainen PET amyloid ligand [C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment Dement Geriatr Cogn Disord 26 4 2008 378 383
183. 11C-PIB positron emission tomography study Ann Neurol 60 1 2006 145 147
184. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Brain 131 Pt 3 2008 665 680
185. G.B. Frisoni, M. Lorenzi, and A. Caroli In vivo mapping of amyloid toxicity in Alzheimer disease Neurology 72 17 2009 1504 1511
186. E.C. Mormino, J.T. Kluth, and C.M. Madison Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects Brain 132 Pt 5 2009 1310 1323
187. D.A. Bennett, J.A. Schneider, and Z. Arvanitakis Neuropathology of older persons without cognitive impairment from two community-based studies Neurology 66 12 2006 1837 1844
188. 18F]FDG PET study Neurology 68 7 2007 501 508
189. Y. Li, J.O. Rinne, and L. Mosconi Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease Eur J Nucl Med Mol Imaging 35 2008 2169 2189
190. 18F-FDG PET for detection of Alzheimer's disease J Nucl Med 48 4 2007 547 552
191. W.J. Strittmatter, A.M. Saunders, and D. Schmechel Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease Proc Natl Acad Sci U S A 90 5 1993 1977 1981
192. I.J. Martins, E. Hone, and J.K. Foster Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease Mol Psychiatry 11 8 2006 721 736
193. K. Ritchie, and A.M. Dupuy The current status of apo E4 as a risk factor for Alzheimer's disease: an epidemiological perspective Int J Geriatr Psychiatry 14 9 1999 695 700
194. E.M. Reiman, K. Chen, and X. Liu Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease Proc Natl Acad Sci U S A 106 16 2009 6820 6825
195. V.L. Villemagne, S. Ataka, and W. Brooks Pattern of Abeta deposition in familial Alzheimer's disease is irrespective of mutation type or cognitive status [abstract] J Nucl Med 49 Suppl 1 2008 216P
196. D.A. Wolk, J.C. Price, and J.A. Saxton Amyloid imaging in mild cognitive impairment subtypes Ann Neurol 65 5 2009 557 568
197. 11C-PIB PET study Neurology 73 2009 754 760
198. R.L. Buckner, A.Z. Snyder, and B.J. Shannon Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory J Neurosci 25 34 2005 7709 7717
199. R.L. Buckner, J.R. Andrews-Hanna, and D.L. Schacter The brain's default network: anatomy, function, and relevance to disease Ann N Y Acad Sci 1124 2008 1 38
200. M. Wermke, C. Sorg, and A.M. Wohlschlager A new integrative model of cerebral activation, deactivation and default mode function in Alzheimer's disease Eur J Nucl Med Mol Imaging 35 Suppl 1 2008 S12 S24
201. H. Engler, A. Forsberg, and O. Almkvist Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain 129 Pt 11 2006 2856 2866
202. C.R. Jack Jr., V.J. Lowe, and S.D. Weigand Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease Brain 132 Pt 5 2009 1355 1365
203. K.A. Ellis, A.I. Bush, and D. Darby The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease Int Psychogeriatr 21 4 2009 672 687
204. S.G. Mueller, M.W. Weiner, and L.J. Thal The Alzheimer's disease neuroimaging initiative Neuroimaging Clin N Am 15 4 2005 869 877 xi-xii
205. A. Eckert, U. Keil, and C.A. Marques Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease Biochem Pharmacol 66 8 2003 1627 1634 (Pubitemid 38373355)
206. K. Leuner, S. Hauptmann, and R. Abdel-Kader Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid Redox Signal 9 10 2007 1659 1675
207. Z. Suo, M. Wu, and B.A. Citron Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimer's disease: an association with early beta-amyloid accumulation J Neurosci 24 13 2004 3444 3452
208. 2+ homeostasis Brain Res 1143 2007 11 21
209. S. Roder, L. Danober, and M.F. Pozza Electrophysiological studies on the hippocampus and prefrontal cortex assessing the effects of amyloidosis in amyloid precursor protein 23 transgenic mice Neuroscience 120 3 2003 705 720
210. E. Capetillo-Zarate, M. Staufenbiel, and D. Abramowski Selective vulnerability of different types of commissural neurons for amyloid beta-protein-induced neurodegeneration in APP23 mice correlates with dendritic tree morphology Brain 129 Pt 11 2006 2992 3005
211. N.M. Kemppainen, S. Aalto, and M. Karrasch Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease Ann Neurol 63 1 2008 112 118
212. J.A. Mortimer Brain reserve and the clinical expression of Alzheimer's disease Geriatrics 52 Suppl 2 1997 S50 S53
213. Y. Stern What is cognitive reserve? Theory and research application of the reserve concept J Int Neuropsychol Soc 8 3 2002 448 460
214. C.M. Roe, M.A. Mintun, and G. D'Angelo Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake Arch Neurol 65 11 2008 1467 1471
215. A. Deshpande, E. Mina, and C. Glabe Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons J Neurosci 26 22 2006 6011 6018
216. L.C. Walker, R.F. Rosen, and H. Levine 3rd Diversity of Abeta deposits in the aged brain: a window on molecular heterogeneity? Rom J Morphol Embryol 49 1 2008 5 11
217. H. Levine 3rd, and L.C. Walker Molecular polymorphism of Abeta in Alzheimer's disease Neurobiol Aging 31 4 2010 542 548
218. R.F. Rosen, L.C. Walker, and H. Levine 3rd PIB binding in aged primate brain: Enrichment of high-affinity sites in humans with Alzheimer's disease Neurobiol Aging 31 4 2010 542 548
219. C.M. Clark, C. Davatzikos, and A. Borthakur Biomarkers for early detection of Alzheimer pathology Neurosignals 16 1 2008 11 18
220. L.M. Shaw, M. Korecka, and C.M. Clark Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics Nat Rev Drug Discov 6 4 2007 295 303
221. K. Hoglund, O. Hansson, and P. Buchhave Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides Neurodegener Dis 5 5 2008 268 276
222. O. Hansson, H. Zetterberg, and P. Buchhave Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment Dement Geriatr Cogn Disord 23 5 2007 316 320
223. O. Hansson, H. Zetterberg, and P. Buchhave Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 3 2006 228 234
224. P.M. Thompson, K.M. Hayashi, and G. de Zubicaray Dynamics of gray matter loss in Alzheimer's disease J Neurosci 23 3 2003 994 1005
225. G.W. Small Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease J Geriatr Psychiatry Neurol 19 3 2006 180 185
226. M.J. de Leon, S. DeSanti, and R. Zinkowski MRI and CSF studies in the early diagnosis of Alzheimer's disease J Intern Med 256 3 2004 205 223
227. P.J. Modrego Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment Curr Alzheimer Res 3 2 2006 161 170
228. E.E. Smith, S. Egorova, and D. Blacker Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia Arch Neurol 65 1 2008 94 100
229. L.A. van de Pol, W.M. van der Flier, and E.S. Korf Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment Neurology 69 15 2007 1491 1497
230. T.R. Stoub, M. Bulgakova, and S. Leurgans MRI predictors of risk of incident Alzheimer disease: a longitudinal study Neurology 64 9 2005 1520 1524
231. G. Spulber, E. Niskanen, and S. Macdonald Whole brain atrophy rate predicts progression from MCI to Alzheimer's disease Neurobiol Aging 2008 DOI:10.1016/j.neurobiolaging.2008.08.018
232. C.R. Jack Jr., M.M. Shiung, and S.D. Weigand Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI Neurology 65 8 2005 1227 1231
233. 18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment Mol Imaging Biol 4 4 2002 283 289
234. G.W. Small, J.C. Mazziotta, and M.T. Collins Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease JAMA 273 12 1995 942 947
235. D.H. Silverman, G.W. Small, and C.Y. Chang Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome JAMA 286 17 2001 2120 2127
236. D.H. Silverman, C.Y. Chang, and J.L. Cummings Prognostic value of regional brain metabolism in evaluation of dementia J Nucl Med 40 Suppl 1 1999 71P
237. C.Y. Chang, and D.H. Silverman Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease Expert Rev Mol Diagn 4 2004 63 69
238. D.H. Silverman, S.S. Gambhir, and H.W. Huang Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits J Nucl Med 43 2 2002 253 266
239. A. Drzezga, N. Lautenschlager, and H. Siebner Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study Eur J Nucl Med Mol Imaging 30 8 2003 1104 1113
240. A. Drzezga, T. Grimmer, and M. Riemenschneider Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET J Nucl Med 46 10 2005 1625 1632
241. R.A. Frank, D. Galasko, and H. Hampel Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease Neurobiol Aging 24 4 2003 521 536
242. H. Zetterberg, and K. Blennow Plasma Abeta in Alzheimer's disease - up or down? Lancet Neurol 5 8 2006 638 639
243. S.B. Raymond, J. Skoch, and I.D. Hills Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology Eur J Nucl Med Mol Imaging 35 Suppl 1 2008 S93 S98
244. M. Hintersteiner, A. Enz, and P. Frey In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe Nat Biotechnol 23 5 2005 577 583